ESMO GOOD SCIENCE BETTER MEDICINE BEST PRACTICE

Declaration of Interests

Introduction

ESMO strives to attain the highest standards of integrity by adopting best practices to enhance our governance and ensure public confidence in our activities. One way in which we meet this objective is through an awareness of potential conflicts of interest.

ESMO has a Disclosure of Interests (DOI) policy that requires individuals acting on behalf of the Society to declare all interests. This policy is currently being revised and strengthened, which is why we are adopting an interim approach for elections held in 2019.

All prospective candidates at the level of President or Director are asked to complete this detailed Declaration of Interests Form. The results will be reviewed by ESMO's Compliance Committee. Since some interests may affect an individual's ability to take on a leadership role at ESMO, matters raised by the Compliance Committee will be taken into account before final candidate selection.

The DOI form (excluding value bands) of the two candidates for each position that are put forward for election will be made available to ESMO members at the time of the Electronic Ballot Vote.

If you have any questions about this process, please contact Katharine Fumasoli (katharine.fumasoli@esmo.org) in the first instance.

Guidance

In each section, please specify interests that you or an immediate family member have held in the last three years with the following for-profit and non-profit organisations:

> Pharmaceutical, diagnostic, biotechnology, medical technology and research companies, private healthcare providers, commercial medical education providers and medical societies.

Also include payments made to your institution on your behalf or in connection with your work, even if you do not make a personal gain. Select 'Institutional' or 'Personal' for each interest, as appropriate.

We ask for approximate financial details in order to understand the size of each interest. This information will be treated confidentially. For each interest, please choose the appropriate value band on the following basis:

i) The total amount received over three years (for income); or
ii) The present value of shares held (for publicly-traded companies); or
iii) The percentage shareholding (for privately-held companies)

You should also declare non-financial interests from which you or an immediate family member have benefited (for example, which may be perceived as having enhanced your career, education or professional education) or which may have given you access to privileged information.

GOOD SCIENCE
BETTER MEDICINE
BEST PRACTICE

Personal Financial Interests

1) Honoraria you have directly received for any speaker, consultancy or advisory role or similar activity (e.g. public speaking, writing engagements, expert testimony or participation in a speaker's bureau) which have been paid directly to you or to your institution.

Company	Description	Value (EUR)	Personal/ Institutional
Amgen	Advisories, Honoraria, Speaker	< €10,000	Institutional
Merck	Advisories, Honoraria, Travel	< €10,000	Institutional
Roche	Advisories, Honoraria, Speaker	< €10,000	Institutional
Lilly	Advisories, Honoraria	< €10,000	Institutional
Astra Zeneca	Advisories, Honoraria	< €10,000	Institutional
BMS	Advisories, Honoraria	< €10,000	Institutional
MSD	Advisories, Honoraria, Travel	< €10,000	Institutional
Ipsen	Advisories, Honoraria, Speaker	< €10,000	Institutional
Sanofi	Advisories, Travel	< €10,000	Institutional

GOOD SCIENCE
BETTER MEDICINE
BEST PRACTICE

1) Continued...

Company	Description	Value (EUR)	Personal/ Institutional

ESMO GOOD SCIENCE BETTER MEDICINE BEST PRACTICE

2) Any role in a for-profit healthcare company for which you are financially compensated (e.g. as an employee, officer or member of the Board of Directors).

Company	Description	Value (EUR)	Personal/ Institutional

3) Details of any stocks or ownership interest that you have in any for-profit healthcare company.

Company	Description	Value (EUR or %)	Personal/ Institutional

4) Licencing fees or royalties that you receive from any Intellectual Property (IP) interests relating to the healthcare or medical industry. Also list any such arrangements that do not currently provide an income but could in the future (i.e. a licence that has been granted).

Company	Description	Value (EUR)	Personal/ Institutional

5) Research funding paid to you or your institution by any for-profit healthcare company specifically in respect of work that you lead (e.g. as a Principal Investigator).

Company	Description	Value (EUR)	Personal/ Institutional
Boehringer	Translational research	< €50,000	Institutional
Amgen	Translational research, clinical trials	< €50,000	Institutional
Roche	Clinical trials, Translational research	< €50,000	Institutional
Genesis Pharma	Translational research	< €50,000	Institutional
Novartis	ranslational research	< €50,000	Institutional
Astra Zeneca	Translational research	< €50,000	Institutional
BMS	Clinical trials, translational research	< €50,000	Institutional
Abbvie	Clinical trials	< €50,000	Institutional
Astellas	Translational research	< €50,000	Institutional
Lilly	Clinical trials	< €50,000	Institutional
Merck	Translational research	< €50,000	Institutional

ESMO GOOD SCIENCE BETTER MEDICINE BEST PRACTICE

5) Continued…

Company	Description	Value (EUR)	Personal/ Institutional

ESMO GOOD SCIENCE BETTER MEDICINE BEST PRACTICE

5) Continued…

Company	Description	Value (EUR)	Personal/ Institutional

GOOD SCIENCE
BETTER MEDICINE
BEST PRACTICE

Non-Financial Interests

6) Details of any non-remunerated activities you have performed for any for-profit healthcare company (e.g. a leadership position, advisory role, principal investigator or project lead).

Details
Principal Investigator for Department of Medical Oncology, Ioannina University Hospital in phase II/III clinical trials sponsored by Amgen, BMS, Lilly, Roche Astra Zeneca, Abbvie, Sanofi

7) Leadership roles you hold in any other medical society, research group, foundation, charity etc. whether remunerated or not.

Details
Member, Scientific Committee of the Hellenic Cooperative Oncology Group (non remunerated): 2012 - present Executive Board Member of the Hellenic Cooperative Oncology Group (non remunerated): 2017 - 2018 Chair, Board of Society for Study of Clonal Heterogeneity of Neoplasia EMEKEN (non remunerated): 2016 - present Chair, ESMO Guidelines Committee: 2015-2019

8) Details of membership or affiliation with any political organisation, pressure group, lobbying organisation or similar association active in the field of oncology.

Details

Other

9) We encourage you to declare any other relationship, role or activity not captured above which you have held within the last three years and that may have the potential to influence your work or your professional behaviour.

Details
Coordinating investigator in HeCOG-sponsored non-commercial investigator-initiated clinical trials Member of the Greek National Pharmacovigilance Committee National expert of Greek National Drug Agency to EMA External assessing expert for the Greek Health Technology Assessment Committee The following companies provided educational grants for support of the Seminar in Molecular Oncology and the Masterclass for Oncology Trainees, organised every year by EMEKEN at Ioannina, 2016-2019, each with <16,000 € annually Amgen Roche Genesis Boehringer Novartis Astra Zeneca BMS Merck MSD Lilly Astellas Sanofi Enorasis Bayer Pfizer Teva

GOOD SCIENCE
BETTER MEDICINE
BEST PRACTICE

No disclosure to make

☐	I confirm that I have no interests to declare

Declaration

I hereby declare that the information I have disclosed is true and complete to the best of my knowledge. By signing this form, I consent to a summary of my interests (excluding financial information) being disclosed to ESMO members if I am selected as a final candidate.

Name:	George Pentheroudakis
Date:	27/05/2019
Signature:	